Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
暂无分享,去创建一个
I. Douglas | A. Malhotra | D. Skiest | I. Rosas | S. Bhagani | L. Del Sorbo | A. Ustianowski | M. Bao | T. Youngstein | S. Savic | N. Bräu | B. Hunter | L. Tsai | M. Aziz | S. Dimonaco | R. Go | B. Matharu | D. J. De La Zerda | H. Spotswood | N. Cooper | M. Waters | A. Cubillo Gracián | E. Graham | Ronaldo C. Go | Antonio Cubillo Gracian
[1] S. Nirkhi,et al. Corona Virus Disease (COVID-19) Pandemic , 2021 .
[2] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .
[3] Keith Sigel,et al. An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.
[4] R. Siegel,et al. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review , 2020, medRxiv.
[5] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply. , 2020, The New England journal of medicine.
[6] Sharon J Peacock,et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.
[7] A. Mastroianni,et al. Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study , 2020, EClinicalMedicine.
[8] M. Massari,et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.
[9] É. Azoulay,et al. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection , 2020, Critical Care.
[10] D. Hanauer,et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19 , 2020, medRxiv.
[11] Jieyun Zhu,et al. Elevated interleukin‐6 is associated with severity of COVID‐19: A meta‐analysis , 2020, Journal of medical virology.
[12] Axel Haverich,et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.
[13] M. Riddle,et al. Clinical outcomes in COVID‐19 patients treated with tocilizumab: An individual patient data systematic review , 2020, Journal of medical virology.
[14] M. Merad,et al. Immunology of COVID-19: Current State of the Science , 2020, Immunity.
[15] Xiaohu Zheng,et al. Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.
[16] R. Assaly,et al. Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis , 2020, Journal of medical virology.
[17] Holger Moch,et al. Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.
[18] M. Netea,et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.
[19] Dong Liu,et al. Tocilizumab treatment in COVID‐19: A single center experience , 2020, Journal of medical virology.
[20] Hui Guo,et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab , 2020, Blood Advances.
[21] N. Chaput,et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report , 2020, Annals of Oncology.
[22] C. Eastin,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.
[23] M. Orsi,et al. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab , 2020, Diagnostic and Interventional Imaging.
[24] Qiurong Ruan,et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.
[25] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[26] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[27] Qin Ning,et al. Clinical and immunological features of severe and moderate coronavirus disease 2019 , 2020 .
[28] D. Schoenfeld,et al. Reappraisal of Ventilator-Free Days in Critical Care Research , 2019, American journal of respiratory and critical care medicine.
[29] D. Furst,et al. A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases , 2018, Rheumatology and Therapy.